Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2020. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of March 31, 2020:
- Issued Share Capital: 5,384,749,852 Ordinary Shares of 25 pence each.
- Treasury Shares: 367,705,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,017,043,902.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely updates the denominator for shareholder notification calculations under FCA rules.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its scope is limited to the statutory notification of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,043,902) for compliance with FCA disclosure thresholds.
- Confirm the number of shares held in Treasury (367,705,950) to calculate the free float accurately.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance metrics.